11
views
0
recommends
+1 Recommend
2 collections
    0
    shares

      Call for Papers: Digital Diagnostic Techniques

      Submit here before November 30, 2024

      About Pathobiology: 3.5 Impact Factor I 8.5 CiteScore I 1.088 Scimago Journal & Country Rank (SJR)

      Call for Papers: Supportive Care - Essential for Modern Oncology

      Submit here before December 31, 2024

      About Oncology Research and Treatment: 2.0 Impact Factor I 3.2 CiteScore I 0.521 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found

      Dynamic Profiling of the Immune Tumor Microenvironment in Locally Advanced Gastric Cancer Treated with Perioperative Chemotherapy

      research-article

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Introduction: In locally advanced gastric cancer (GC), FLOT represents the standard perioperative regimen and combination with immunotherapy is under investigation. However, the role of immune tumor microenvironment (TME) is poorly recognized in this setting. We aimed to study TME characteristics and dynamics during FLOT. Methods: Paired biopsy (PRE) and surgical (POST) samples of 25 patients treated with FLOT were prospectively analyzed. After collection of clinic-pathological data, NanoString analyses were performed. The primary objective of the study was to assess the changes induced by chemotherapy in POST compared to PRE samples. Results: The unsupervised hierarchical method analysis clearly distinguished PRE and POST samples, even though some cases showed high immune gene expression at baseline. When POST samples were compared with PRE, a differential expression in hyper-expressed gene sets related to cytotoxicity, T-cell functions, complement system, tumor necrosis factor superfamily, cell cycle, and regulation was recognized. Downstaging of the primary tumor (T-regression, measured by pathologic compared to clinical T stage) was the covariate most frequently associated with these changes. Using the immune cell profiling, cases with T-regression reported a significant increase of T, CD8+ T and B cells and a decrease in mast cells, while nonresponders demonstrated an increase of T, B, cytotoxic, and mast cells. Conclusion: Our analysis shows that FLOT significantly influences immune TME of GC. While relevant modifications preferentially occur in tumors showing primary tumor regression, response to treatment seems to be associated with a specific immune profile.

          Related collections

          Author and article information

          Journal
          OCL
          Oncology
          10.1159/issn.0030-2414
          Oncology
          Oncology
          S. Karger AG
          0030-2414
          1423-0232
          2023
          August 2023
          12 June 2023
          : 101
          : 7
          : 435-445
          Affiliations
          [_a] aUnit of Medical Oncology, Ospedale Misericordia, Azienda USL Toscana Sud Est, Grosseto, Italy
          [_b] bDepartment of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Pisa, Italy
          [_c] cUnit of Medical Oncology, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy
          [_d] dDepartment of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy
          [_e] eUnit of Esophageal Surgery, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy
          [_f] fSant’Anna School of Advanced Studies, Pisa, Italy
          Author information
          https://orcid.org/0000-0001-9740-0219
          https://orcid.org/0000-0002-4937-9942
          https://orcid.org/0000-0001-8329-8989
          Article
          530853 Oncology 2023;101:435–445
          10.1159/000530853
          37307799
          aa111a1e-a863-4767-8601-c024488f65c4
          © 2023 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.

          History
          : 26 October 2022
          : 21 April 2023
          Page count
          Figures: 5, Tables: 2, Pages: 11
          Funding
          This study was partially supported by University of Pisa, Progetti di Ricerca di Ateneo (PRA) 2020-2021 (no grant number) to Prof. Chiara Cremolini. The funding institution had no role in study design, in the collection, analysis, and interpretation of data, in the writing of the report, and in the decision to submit the article for publication.
          Categories
          Clinical Translational Research

          Medicine
          Tumor microenvironment,NanoString,Gastric cancer,5-Fluorouracil/leucovorin, oxaliplatin, docetaxel,Immune profiling

          Comments

          Comment on this article